Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus

NCT03502694 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped sponsor decision

Conditions

Metapneumovirus

Interventions

DRUG: Lumicitabine
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC